CEL-SCI Closes Underwritten Public Offering - Quick Facts

(RTTNews) - CEL-SCI Corp. (CVM), a late-stage oncology company, announced that it has closed an underwritten public offering of units consisting of an aggregate of 5.24 million shares of common stock and warrants to purchase an aggregate of 5.24 million shares of common stock.

The securities sold are inclusive of the exercise in full by the underwriters of the over-allotment option to purchase an additional 471,190 shares of common stock and warrants to purchase 471,190 shares of common stock, at a combined price of $0.63, and resulted in aggregate gross proceeds of about $3.3 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company.

The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 11, 2018 and have an exercise price of $1.25.

The warrants have been approved for an unpriced quotation on the OTC Bulletin Board under the symbol "CSCIW," however no market for the warrants has developed as of the date of this press release.